Table 1. Clinical trial complexity characteristics in phase 2 and phase 3

The table below summarises complexity benchmarks for phase 2 and phase 3 clinical studies across various scientific and executional characteristics.

Adapted from Getz, K., Smith, Z., & Kravet, M. (2023). Protocol design and performance benchmarks by phase and by oncology and rare disease subgroups. Therapeutic Innovation & Regulatory Science, 57(1), 49-56.
Source: Tufts CSDDGet the dataCreated with Datawrapper